We sought to review outcomes of @entity1 who have immunoglobulin light-chain @entity2783 of the IgM type. Fifty @entity1 with a serum IgM monoclonal protein and biopsy-proven amyloid were evaluated. The percentages of @entity1 presenting with @entity8 were 44%, 32%, 14%, and 10%, respectively. Forty-two percent had an @entity10805 spike in the serum greater than 1.5 g/dL, and 14% had an IgM peak greater than 3 g/dL. @entity2783 was diagnosed easily by biopsies of the subcutaneous fat, rectum, and bone marrow, which demonstrated deposits in 84%, 72%, and 50%, respectively. The median survival of all @entity1 was 24.6 months. Fifty-three percent of all @entity204 were due to @entity299 . Twelve percent died of @entity1576 , and 7% each died of @entity8057 , @entity1578 , and @entity177 . Of the 22 @entity1 with @entity296 , the median survival was 11.1 months and fewer than 10% survived 5 years. Of the 28 @entity1 without @entity296 at diagnosis, the median survival was 27 months, with approximately 30% surviving 5 years. We conclude that the presence of @entity296 and an increased @entity1011 concentration had the greatest impact on survival.

XXXX with IgM monoclonal gammopathies.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['cardiac, renal, hepatic, and pulmonary amyloid'] @entity296 :: ('MESH:D009202', 'Disease') :: ['amyloid cardiomyopathy'] @entity10805 :: ('9172', 'Gene') :: ['M-protein'] @entity2783 :: ('MESH:D000686', 'Disease') :: ['Amyloidosis', 'amyloidosis'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure'] @entity1578 :: ('MESH:D017093', 'Disease') :: ['hepatic failure'] @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory failure'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac amyloidosis'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity8057 :: ('MESH:D008258', 'Disease') :: ['macroglobulinemia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths']
@entity2783 :: (MESH:D000686,Disease) :: ['Amyloidosis']
